UPDATE 1-Dynavax's hep B vaccine meets goals in late-stage study

Jan 7 (Reuters) - Dynavax Technologies Corp said its experimental hepatitis B vaccine was found to be safe and effective in a late-stage study, sending its shares up 9.4 percent in premarket trading.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.